The European Society of Cardiology Congress conference wrapped up this week in London. Here’s a roundup of news from the overseas meeting of interventional cardiologists, dominated by data on fractional flow reserve technology. FFR: St. Jude touts 5 year data showing long-term benefits St. Jude Medical (NYSE:STJ) released 5-year data from a trial comparing the use […]
Cardiovascular
Welcome to MassDevice's Cardiovascular Hub, your resource for the latest news in cardiac implants, structural heart, heart valves, stents and more. Stay informed about the innovations and business news shaping the cardiovascular device industry.
🫀 Narrow your focus with these categories:
Cardiac Implants | Structural Heart | Pulsed-Field Ablation
Here are top cardiology features from MassDevice and its sister publications (and scroll down to read the latest cardiology device news from MassDevice):
+ LVADs save lives: So why aren’t more available?
+ How Medtronic uses nitinol to improve the structure and effectiveness of heart devices
+ How Abbott designed the world’s first dual-chamber leadless pacemaker system
+ J&J used RWE for expanded indications — and you can, too
+ 7 cardiology startups you need to know
Latest Cardiology News
Thoratec trial pits HeartMate PHP against Abiomed’s Impella
Thoratec (NSDQ:THOR) said today that it’s launching a clinical trial pitting its HeartMate PHP device against Abiomed‘s (NSDQ:ABMD) Impella 2.5 percutaneous heart pump. The Shield II trial is slated to enroll up to 425 patients at up to 60 sites, randomized against the Impella device at a 2:1 ratio. The trial’s primary endpoint is non-inferiority based on […]
FDA warns iPhone ECG maker Cardiac Designs
The FDA published a warning letter it sent to Cardiac Designs over issues associated with the company’s lack of design validation and how it handles and analyzes complaints about its device. The letter was sent after an FDA inspector visited the company’s Round Rock, Texas location in June. Utah-based Cardiac Designs produces an Apple (NSDQ:AAPL) iPhone-based electrocardiogram […]
TMVI: Elron leads $5m Series A round for Coramaze
Coramaze Technologies said it raised a $5 million (€4.5 million) Series A round for the transcatheter mitral valve implant it’s developing. The round was led by a $3.9 million (€3.5 million) contribution from Israel’s Elron Electronic Industries (TASE:ELRN), which said it now owns 28% of Munich-based Coramaze. Existing backers High-Tech Gründerfonds and SeedCapital Dortmund also participated with a pool of private investors, […]
HeartWare plunges on Valtech Cardio buyout
Shares of HeartWare International (NSDQ:HTWR) plunged 20.8% after the company announced a buyout of Israeli replacement heart valve maker Valtech Cardio. HTWR shares closed at $64.82 apiece yesterday as investors reacted to the highly dilutive terms of the deal, which was worth some $929 million based on HeartWare’s closing price the day before it was announced. It’s now worth about […]
Abbott closes $250m Tendyne buy
Abbott (NYSE:ABT) said today that it closed the $250 million acquisition of replacement mitral valve maker Tendyne Holdings. Abbott said in July that it put another $225 million on top of the stake it already owned in Roseville, Minn.-based Tendyne, which raised a $25 million Series C round in April 2014. The total value of the Tendyne deal […]
HeartWare inks $929m deal for Valtech Cardio’s mitral and tricuspid valves
HeartWare International (NSDQ:HTWR) said yesterday that it agreed to put roughly $929 million on the table for Israeli replacement heart valve maker Valtech Cardio. Terms of the deal call for an up-front payment of 4.4 million shares of HeartWare stock, which would be worth about $360 million at yesterday’s closing price of $81.81. The buyout also […]
Abbott’s Absorb fares well again against Xience in Japanese study
Abbott (NYSE:ABT) today released positive data from a Japanese study of its Absorb fully dissolving heart stent that pitted it against its own Xience permanent drug eluting stent. The results were announced at the European Society of Cardiology’s annual meeting in London. The 400 patient multi-center, randomized Absorb study, published in the European Heart Journal, set […]
HeartFlow study shows reduced unnecessary ICA with FFRct
HeartFlow presented data from a clinical trial of its FFRct analysis that showed a significant reduction in unnecessary invasive coronary angiography after evaluation with the device. The data was presented at European Society of Cardiology’s annual meeting in London today. HeartFlow’s FFRct platform is an imaging approach that helps physicians treat coronary artery disease by getting […]
ESC guidelines updated to include subcutaneous defibs
The European Society of Cardiology updated its treatment guidelines for ventricular arrhythmia patients to include subcutaneous implantable cardioverter defibrillators. The announcement was made at the society’s annual meeting in London on Saturday. The new guidelines recommend the use of the S-ICD units as a possible alternative to transvenous defibrillators in patients with an ICD indication […]
St. Jude Medical’s Nanostim leadless pacer meets 6-month safety, efficacy goals
The Nanostim implantable pacemaker made by St. Jude Medical (NYSE:STJ) met its 6-month safety and efficacy endpoints, according to data presented over the weekend at the annual meeting of the European Society of Cardiology in London and published in the New England Journal of Medicine. The Leadless II study enrolled 526 patients in the primary cohort, with 300 […]